Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
Fenstermaker et al – 2016 (view as PDF)...
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
- Seeking Series B investment for next phase of clinical trials
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
Publications
Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins
Cai et al -2017 (view as PDF)...
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients
Berinstein et al – 2015 (view as PDF)...
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, Adida and Altieri -1997 (view as PDF)...
An informative article in advertising feature in Nature Biotechnology Sep 2017
Biopharmadealmakers.nature.com | September 2017; Oxford Vacmedix Ltd.: harnessing the power of immunotherapy to treat and monitor cancer View in PDF...
Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins
Lili Cai, Jianbo Zhang et al, Oncotarget August 24, 2017 View in PDF...
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief CJ, van der Burg SH.  Nat Rev Cancer. 2008 May;8(5):351-60....
Therapeutic Cancer Vaccines
Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH.  J Clin Invest. 2015 Sep;125(9):3401-12. View in PDF...
​Comparing Pooled Peptides with Intact Protein for Accessing Cross-presentation Pathways for Protective CD8 and CD4 T Cells
Zhang, H et al.  The Journal of Biological Chemistry, VOL.284,NO.14,pp.9184–9191, April 3,2009 View in PDF...
Contact Us
If you have any questions or want to get in touch, please contact our team.
(c) 2025 Oxford Vacmedix UK Limited | Company Registration: 07994205
English